Der ALS-Podcast (Der Podcast zur Amyotrophen Lateralsklerose)
by Prof. Dr. Thomas Meyer
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 ~2x weekly·57 episodes·Last published 2mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHost
Recent guests
Recent episodes
ALS-Podcast #60 zu Offene Fragen zur ALS mit Patrick Großmann
Jun 23, 2026
1h 05m 32s
ALS-Podcast #59 zu Physikalische Ansätze der Therapieentwicklung mit Prof. Dr. Enrico Klotzsch
Jun 16, 2026
56m 26s
ALS-Podcast #58 zum Prognosefaktor NfL mit Peggy Schumann
Apr 14, 2026
58m 30s
ALS-Podcast #57 zu Botulinumtoxin bei der ALS mit Dr. Ute Weyen
Mar 16, 2026
59m 22s
ALS-Podcast #56 zu Individuellen Heilversuchen & Off-Label-Behandlungen mit PD Dr. Patrick Weydt
Feb 23, 2026
47m 25s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
Resolving iTunes ID\u2026 if this persists, the podcast may not be indexed on Apple Podcasts.
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/23/26 | ALSgenetic therapy+4 | Patrick Großmann | VTx-002SPG302+7 | — | ALSgenetic therapy+5 | — | 1h 05m 32s | ||
| 6/16/26 | Physikalische Ansätze der TherapieentwicklungDatenbasierte Medikamenten-Entwicklung+5 | Prof. Dr. Enrico Klotzsch | — | — | ALSMedikamente+8 | Boris Canessa ALS Stiftung | 56m 26s | ||
| 4/14/26 | Neurofilament Light ChainALS prognosis+3 | Peggy Schumann | Boris Canessa ALS StiftungCharité+1 | — | NfLALS+8 | — | 58m 30s | ||
| 3/16/26 | BotulinumtoxinALS+4 | Dr. Ute Weyen | Universitätsklinikum Bergmannsheil | — | BotulinumtoxinALS+5 | — | 59m 22s | ||
| 2/23/26 | individuelle HeilversucheOff-Label-Behandlungen+4 | PD Dr. Patrick Weydt | Universitätsklinikum Bonn | — | ALSindividuelle Heilversuche+4 | — | 47m 25s | ||
| 1/29/26 | ALSTroponin T+3 | PD Dr. Patrick Weydt | Universitätsklinikum BonnCharité+3 | — | ALSTroponin T+5 | — | 1h 01m 15s | ||
| 12/22/25 | ALSgenetic therapy+4 | Patrick Großmann | Eli Lilly Inc. | — | ALSgenetic therapy+7 | — | 1h 28m 07s | ||
| 12/22/25 | AtemwegeSekretmanagement+3 | Ansgar Schütz | Charité | — | ALSSekretmanagement+5 | — | 1h 02m 04s | ||
| 10/28/25 | KognitionVerhalten+4 | Prof. Dr. Johannes Prudlo | Universitätsmedizin RostockDeutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) | — | ALSFTD+6 | — | 1h 07m 59s | ||
| 10/28/25 | ALS-PhänotypenOnset+5 | Dr. Susanne Spittel | CharitéAPST Research | — | ALSPhänotypen+6 | — | 1h 13m 51s |
Showing 10 of 10
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.